Hormone Therapy Boosts Semaglutide Weight Loss
Middle-aged women taking hormone therapy for menopause symptoms achieve greater weight loss when using GLP-1 medications like semaglutide, according to research presented on October 22, 2026, at the annual meeting of The Menopause Society in San Diego. At a one-year follow-up, patients using both hormone therapy and semaglutide lost an average of 11% of their total body weight, compared to 9.5% for patients taking semaglutide alone.
Researchers Evaluate 3,900 Overweight Women Using GLP-1 Drugs
The research evaluated approximately 3,900 women aged 45 and older, with an average age of 57, all falling into the overweight or obese body-mass index category. Investigators analyzed data from nearly 2,400 women taking semaglutide, marketed as Ozempic and Wegovy, and nearly 1,500 women taking tirzepatide, marketed as Mounjaro and Zepbound. Lead researcher Dr. Regina Castaneda, a postdoctoral fellow with Mayo Clinic Florida, noted that the investigation stands as one of the largest examinations linking GLP-1 drugs with hormone therapy.
Semaglutide Outperforms Tirzepatide in Combination Trials
While both medications aided weight loss when paired with hormone therapy, the synergistic effect appeared stronger with semaglutide. Approximately 22% of women on the semaglutide and hormone therapy combination lost 20% or more of their body weight, versus 18% of those using semaglutide alone. Meanwhile, 6% of combination users shed 30% or more of their body weight, compared to 4% in the single-therapy group. Tirzepatide showed modestly greater weight loss at a three-month mark of 6.6% versus 5.9%, and a higher proportion of users achieved a 5% or greater reduction in total body weight at 88% compared to 84%, though the gap narrowed by the end of the study period.
Tirzepatide Outperforms Semaglutide Through Dual-Action Signaling
Castaneda explained that preclinical data suggests a potential synergistic effect between estrogen and GLP-1 signaling, which accounts for the enhanced weight loss outcomes. Tirzepatide users ultimately lost more weight, averaging about 35 pounds after 15 months, reflecting tirzepatide’s dual-action mechanism targeting both GIP and GLP-1 receptors compared to semaglutide’s single-receptor focus. Researchers emphasized that weight loss is not an indication for menopause hormone therapy, and patients should not initiate hormone treatments solely to shed pounds.
Personalized Midlife Weight Management Strategies
The Menopause Society notes that about 1 in 5 women aged 50 to 64 currently use or have used a GLP-1 medication, representing the highest usage demographic in the United States. Dr. Stephanie Faubion, medical director for The Menopause Society, stated that these findings indicate hormone therapy influences how midlife women respond to GLP-1 treatments. Investigators caution that findings presented at medical conferences remain preliminary until published in a peer-reviewed journal, and patients must discuss individual health histories with a clinician to weigh the benefits and risks of combining these therapies.
Why Menopause Causes Weight Gain and GLP-1 Risks?
Why do women frequently gain weight during the menopause transition?
As estrogen levels decline during perimenopause and menopause, muscle mass naturally breaks down while the body craves more calories. This hormonal shift often leads to increased insulin resistance and stubborn fat accumulation around the waist, even without changes in diet or exercise habits.
What specific risks are associated with combining GLP-1 drugs and hormone therapy?
While the study focused on weight-loss efficacy, both treatments carry individual side effects and health considerations. Hormone therapy carries specific risks depending on personal health history, while GLP-1 medications are designed for long-term use and require continuous administration to maintain results.
Can women start taking hormone therapy specifically to lose weight?
No, medical experts explicitly state that weight loss is not an indication for menopause hormone therapy. Clinicians recommend hormone therapy for managing menopausal symptoms like hot flashes, rather than as a primary weight-loss tool.
Related reading